SynAct Pharma’s CFO Björn Westberg leaves for new leading position
Kurs
+7,56%
Likviditet
5,06 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-18 | 07:30 | Bokslutskommuniké 2025 |
| 2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2025-05-27 | - | Årsstämma |
| 2025-05-27 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-18 | - | Bokslutskommuniké 2024 |
| 2024-12-13 | - | Extra Bolagsstämma 2024 |
| 2024-10-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-04 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2023-01-12 | - | Extra Bolagsstämma 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-23 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2021-05-21 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-11-08 | - | Extra Bolagsstämma 2019 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-13 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2019-05-10 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2018-05-15 | - | Årsstämma |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company’s CFO is leaving the company when a successor has been appointed.
“Our current CFO Björn Westberg has decided to pursue another opportunity and will leave the company later this year when his successor is appointed. We wish him all the best in the future,” said SynAct CEO Jeppe Øvlesen.
“During Björn Westberg’s time at the company, we secured financing, extended the runway into 2027, and put the company on a promising development path. The process of identifying his successor is ongoing, and we look forward to presenting the new CFO as part of our updated management team that is aimed at continuing the development of SynAct’s pipeline with a focus on the lead compound resomelagon (AP1189) currently in Phase 2b development in Rheumatoid Arthritis, which has the potential to be a new well-tolerated oral treatment option,” Jeppe Øvlesen continued.
“It has been an exciting journey being part of SynAct since 2023, and I am satisfied that SynAct is now in a strong financial position together with a promising development pipeline,” said SynAct’s CFO, Björn Westberg.
For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.